- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Drug Pricing Challenges and Navigating the IRA
In this Pharm Exec Podcast episode, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, discusses the biggest drug pricing challenges today, what companies should consider for drug pricing (from a legal perspective), the status and potential impact of the Inflation Reduction Act, and drug pricing recommendations.
How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview:
- The biggest drug pricing challenges today
- Current efforts to lower drug pricing
- Whatcompanies should consider as it relates to drug pricing from a legal perspective
- The status of the Inflation Reduction Act (IRA), specifically what should companies be watching for
- Potential impact on companies from the IRA
- IRA milestones we will be seeing through the end of the year
- Drug pricing recommendations (from a legal perspective)
About the speaker
Alice Valder Curran is a life sciences regulatory expert and partner at Hogan Lovells with a particular emphasis on pharmaceutical pricing and market access.As an influential policy advocate before Congress and the Executive Branch, Curran has built a market-leading practice serving drug developers in the areas of drug pricing, regulatory innovation, and market access. The Financial Times recognized her in its awards, “Most Innovative Legal Practitioner,” for her work developing the multiple best prices reporting option, which was codified by CMS in regulation. With Congress’ recent adoption of significant changes to drug pricing regulation, she is a sought-after advisor on the economic and policy implications of the IRA.
About the Pharm Exec Podcast
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
